EUCTR2012-005499-33-DE进行中（未招募）不适用
Relative bioavailability trial to investigate the pharmacokinetics of tapentadol following the administration of 3 prototype tapentadol 25 mg prolonged release (PR) granule formulations compared to a Palexia® PR 25 mg tablet in healthy adult subjects.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Subjects have given written informed consent to participate.
- •2. White, male, and aged 18 years to 55 years, inclusive.
- •3. Body mass index between 18.5 kg/m2 and 30.0 kg/m2, inclusive, with a lower body weight limit of 50.0 kg.
- •4. In good health as determined by medical history (including surgical history), physical examination, 12-lead ECG, vital signs, and safety laboratory parameters.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 48
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria (Enrollment Visit for Part 1 and Part 2)
- •1. Resting pulse rate is less than 50 beats or equal and greater than 90 beats per minute after 5 minutes rest in a supine position.
- •2. Resting blood pressure after 5 minutes rest in a supine position. Systolic blood pressure is less than 110 mmHg or equal and greater than 140 mmHg. Diastolic blood pressure is less than 60 mmHg or equal and greater than 90 mmHg.
- •3. QT or QTcB interval prolongation of greater than 500 ms.
- •4 a) Any out-of-reference range value for: gamma-glutamyl transferase, serum creatinine, prothrombin time, and international normalized ratio.
- •b) Any exclusion range met for urinalysis and laboratory parameters: alanine transaminase, aspartate transaminase, alkaline phosphatase, total bilirubin, glucose (fasted), lactate dehydrogenase, total protein, creatine kinase, hemoglobin, hematocrit, white blood cell count, and platelets.
- •c) Any out-of-reference range value for any other clinical laboratory parameter that is judged as clinically relevant by the investigator.
- •5. Evidence for thyroid disease.
- •6. History of orthostatic hypotension.
- •7. Positive or missing test for human immunodeficiency virus type 1/2 antibodies and antigen, hepatitis B surface antigen and core antibodies, or hepatitis C antibodies.
- •8. Participation in another clinical trial within the 30 days before the Enrollment Visit, or a previous IMP within a period less than 10 times its half-life, whichever is longer.
- •9. History of drug abuse, or alcohol abuse or has an acute intoxication with centrally acting drugs.
- •10. Positive or missing alcohol breath test.
- •11. Positive or missing drugs of abuse test.
- •12. History of gastric surgery, existing or suspicion of having a paralytic ileus, or current significant medical illness.
- •13. History of clinically significant allergies, especially known hypersensitivity/intolerance or contraindications to opioids, opioid antagonists, or any excipients of the drug formulation.
- •14. Any contraindication for tapentadol or drugs with mu-opioid receptor agonist activity, i.e., subjects with significant respiratory depression, and subjects with acute or severe bronchial asthma or hypercapnia.
- •15. History of seizure disorder, epilepsy, or mild or moderate brain injury, stroke, transient ischemic attack, brain neoplasm within 1 year of enrollment.
- •16. Regular use of any prescribed or non-prescribed medications within 14 days before the Enrollment Visit. Use of monoamine oxidase inhibitors within 21 days before the Enrollment Visit.
- •17. Not able to abstain from consuming products containing methylxanthine, alcohol, or quinine within 24 hours of the first administration of tapentadol; or Seville oranges or products containing grapefruit juice or poppy seeds within 72 hours of the first administration of tapentadol until discharge from the trial site.
- •18. Blood donation or acute loss of blood within 3 months before the Enrollment Visit, or intention to donate blood or blood products during the trial or within 1 month following the completion of the trial.
- •19. Known or suspected of not being able to comply with the requirements of the trial protocol.
- •20. Not able to communicate meaningfully with the investigator and staff.
- •21. Habitually smoking more than 10 cigarettes, 2 cigars, or 2 pipes of tobacco per day within the last 6 months before the Enrollment Visit.
- •22. Unable to swallow solid, oral dosage forms whole with the aid of water.
- •23. Employee
研究者
相似试验
进行中（未招募）
1 期
Phase I Relative Bioavailability and food effect studyEUCTR2016-002895-29-DEBayer AG
进行中（未招募）
1 期
Phase I relative bioavailability and food effect studyEUCTR2016-002813-24-DEBayer AG
已完成
不适用
Relative bioavailability study to investigate a potential interaction between dolutegravir (DTG) and tenofovir alafenamide fumarate/emtricitabine (F/TAF) administered as paediatric tablet formulations.NL-OMON51616Radboud Universitair Medisch Centrum16
已完成
不适用
A clinical study to compare the performance of a novel solid dose injection of octreotide with a reference productAcromegalyISRCTN72107545Glide Pharmaceutical Technologies Ltd20
进行中（未招募）
不适用
A study to compare a pediatric tablet or suspension of elvitegravir verses the adult 150 mg tablet in healthy adult volunteersHuman Immunodeficiency Virus (HIV-1) InfectionMedDRA version: 17.1Level: LLTClassification code 10020192Term: HIV-1System Organ Class: 100000004862EUCTR2015-000725-37-Outside-EU/EEAGilead Sciences, Inc.78